Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia

Haematologica. 2008 Aug;93(8):1260-1. doi: 10.3324/haematol.12801. Epub 2008 Jun 2.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Amino Acid Substitution
  • Antisickling Agents / therapeutic use
  • Female
  • Humans
  • Hydroxyurea / therapeutic use
  • Janus Kinase 2 / genetics*
  • Leukocyte Count
  • Male
  • Middle Aged
  • Polycythemia Vera / blood*
  • Polycythemia Vera / drug therapy
  • Polycythemia Vera / genetics*
  • Polymorphism, Single Nucleotide
  • Thrombocythemia, Essential / blood*
  • Thrombocythemia, Essential / drug therapy
  • Thrombocythemia, Essential / genetics*

Substances

  • Antisickling Agents
  • JAK2 protein, human
  • Janus Kinase 2
  • Hydroxyurea